HEAD START
Migraines affect one in five women and one in 15 men in the UK. And although there is currently no cure for the debilitating condition, a new preventative treatment called eptinezumab, sold under the brand name Vyepti, has been approved for use by the NHS.
The treatment will be provided to patients who have been unsuccessful with three previous preventative medications or who experience migraines on four or more days a month. Given through an intravenous drip every 12 weeks, the medicine targets proteins that cause blood vessels in the brain to swell.
Here, speaks to Dr Avinash Kumar Hari Narayanan) about the condition’s main causes and the alternative measures that sufferers can take to reduce their risk of migraine attacks.
